Fujifilm plans to invest approximately €25 million to install new production facilities for chemical mechanical planarization (CMP) slurries, which are used in advanced semiconductors, as well as enhance existing facilities for photolithography-related materials at its site in Antwerp, Belgium.
Fujifilm hast completed the construction of a new factory for advanced semiconductor materials in Pyeongtaek City, Korea. The new factory will produce color filter materials for image sensors. The new factory is scheduled to be fully operational by the end of December 2024.
Fujifilm announced an additional investment of $1.2 billion in its large-scale cell culture contract development and manufacturing organization (CDMO) business to further expand the planned Fujifilm Diosynth Biotechnologies facility in Holly Springs, North Carolina, bringing the total investment in the facility to over $3.2 billion. Plans for the new site were unveiled in September last year.
Fujifilm Diosynth Biotechnologies unveiled its new $2 billion large-scale cell culture manufacturing facility in Holly Springs, North Carolina, US.
Japan’s Fujifilm has agreed to acquire Entegris’ electronic chemicals business for $700 million. The transaction is expected to close by the end of 2023, subject to regulatory approval and other customary conditions.
Responding to rising market demand, Japan’s Fujifilm is spending $188 million to establish a manufacturing facility for cell culture media in Research Triangle Park, North Carolina, USA. The site – Fujifilm’s fifth worldwide – will be operated by subsidiary Fujifilm Irvine Scientific.
Fujifilm is preparing to invest $1.6 billion to ramp up the cell culture manufacturing services of its CDMO subsidiary Fujifilm Diosynth Biotechnologies.
Fujifilm Irvine Scientific, part of Japan’s Fujifilm Holdings, will acquire Shenandoah Biotechnology, a US-based, privately held manufacturer of recombinant proteins. Financial terms of the deal, which is expected to close later this month, were not disclosed.
Fujifilm Diosynth Biotechnologies is investing £400 million to expand its Teesside site in northeast England, where it makes the active ingredient for the Novavax Covid-19 vaccine. The Japanese company said the expanded facilities are set to open in 2023 or early 2024, creating as many as 350 “highly skilled jobs” in contract manufacturing.
Japan’s Fujifilm has pledged an investment package of about $850 million to accelerate the growth of its core bio CDMO subsidiary Fujifilm Diosynth Biotechnologies by expanding capabilities at undisclosed locations in the US and UK. Initial engineering studies are underway and the projects are scheduled to begin operating by late 2023.
Fujifilm Diosynth Biotechnologies has chosen Holly Springs in North Carolina as the site of its new large-cell culture production site in the US. The company first announced its plans in January, saying it planned to spend more than $2 billion on the project, which will be the largest end-to-end cell culture biopharma CDMO facility in North America when it starts up by spring 2025.
Fujifilm Diosynth Biotechnologies, a subsidiary of Japan’s Fujifilm Corp., has announced plans to spend more than $2 billion to build a new large-scale cell culture production site in the US to accelerate the growth of its biopharma CDMO business.
